公开(公告)号：US20050152908A1

公开(公告)日：2005-07-14

申请号：US10980850

申请日：2004-11-03

申请人： Choong-Chin Liew ,  Thomas Yager ,  Adam Dempsey ,  Samuel Chao

发明人： Choong-Chin Liew ,  Thomas Yager ,  Adam Dempsey ,  Samuel Chao

IPC分类号： A61K39/395 ,  C07H21/04 ,  C07K14/00 ,  C07K16/30 ,  C12N20060101 ,  C12Q1/68 ,  G01N33/574

CPC分类号： C07K16/303 ,  C07K14/00

摘要： The invention relates to the identification and selection of biomarkers which demonstrate particular advantage in identifying individuals having liver cancer. The invention further relates to useful combinations of biomarkers for diagnosing liver cancer. The invention further provides for the polynucleotides and polypeptides and kits thereof for use as a tool to diagnose disease and to monitor the efficacy of therapeutic regimens. The invention further provides a method of selecting biomarker combinations and the combinations thus identified for diagnosis of liver cancer. Also encompassed by the invention are screening methods to identify therapeutic targets for treating liver cancer, and identify single nucleotide point mutations related to liver cancer.

摘要翻译： 本发明涉及鉴定和选择生物标志物，其在鉴定具有肝癌的个体方面具有特别的优势。 本发明还涉及用于诊断肝癌的生物标志物的有用组合。 本发明进一步提供多核苷酸和多肽及其试剂盒，用作诊断疾病和监测治疗方案疗效的工具。 本发明还提供了选择生物标志物组合的方法以及由此鉴定用于肝癌诊断的组合。 本发明还包括鉴定用于治疗肝癌的治疗靶标的筛选方法，以及鉴定与肝癌相关的单核苷酸点突变。

公开(公告)号：US08921074B2

公开(公告)日：2014-12-30

申请号：US12384914

申请日：2009-04-10

申请人： Choong-Chin Liew ,  Samuel Chao

发明人： Choong-Chin Liew ,  Samuel Chao

IPC分类号： C12P19/34 ,  G01N33/574 ,  C12Q1/68 ,  G06F19/24 ,  G06F19/20

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2600/166 ,  G01N33/57419 ,  G01N2800/50 ,  G01N2800/56 ,  G06F19/12 ,  G06F19/20 ,  G06F19/24

摘要： A method of determining a probability that a human test subject has colorectal cancer as opposed to not having colorectal cancer is disclosed. The method comprises, for each gene of a set of one or more genes selected from the group consisting of ANXA3, CLEC4D, IL2RB, LMNB1, PRRG4, TNFAIP6 and VNN1: determining a level of RNA encoded by the gene in blood of the test subject, thereby generating test data; providing positive control data representing levels of RNA encoded by the gene in blood of human control subjects having colorectal cancer, and providing negative control data representing levels of RNA encoded by the gene in blood of human control subjects not having colorectal cancer; and determining a probability that the test data corresponds to the positive control data and not to the negative control data, where the probability that the test data corresponds to the positive control data and not to the negative control data represents the probability that the test subject has colorectal cancer as opposed to not having colorectal cancer.

摘要翻译： 公开了一种确定人类受试者具有结肠直肠癌而不是不具有结肠直肠癌的可能性的方法。 对于选自ANXA3，CLEC4D，IL2RB，LMNB1，PRRG4，TNFAIP6和VNN1的一组或多种基因的每个基因，该方法包括：测定受试对象的血液中基因编码的RNA水平 从而生成测试数据; 提供表示具有结肠直肠癌的人类对照受试者的血液中基因编码的RNA水平的阳性对照数据，并提供表示不具有结肠直肠癌的人类对照受试者的血液中由该基因编码的RNA水平的阴性对照数据; 并且确定测试数据对应于阳性对照数据而不是阴性对照数据的概率，其中测试数据对应于阳性对照数据而不是阴性对照数据的概率表示测试对象具有 结肠直肠癌相对于没有结肠直肠癌。

公开(公告)号：US20130165336A1

公开(公告)日：2013-06-27

申请号：US13603094

申请日：2012-09-04

申请人： Choong-Chin Liew ,  Thomas Yager ,  Adam Dempsey ,  Samuel Chao

发明人： Choong-Chin Liew ,  Thomas Yager ,  Adam Dempsey ,  Samuel Chao

IPC分类号： G01N21/64

CPC分类号： C12Q1/6883 ,  C12Q2600/158 ,  Y02A90/22 ,  Y02A90/24 ,  Y02A90/26

摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens.

摘要翻译： 本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并且可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。 使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和 蛋白质。 本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。

公开(公告)号：US08239136B2

公开(公告)日：2012-08-07

申请号：US11585666

申请日：2006-10-23

申请人： Choong-Chin Liew ,  Mark Han ,  Thomas Yager ,  Samuel Chao ,  Run Zheng ,  Hongwei Zhang

发明人： Choong-Chin Liew ,  Mark Han ,  Thomas Yager ,  Samuel Chao ,  Run Zheng ,  Hongwei Zhang

IPC分类号： G01N33/48

CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/16 ,  G06F19/12 ,  G06F19/18 ,  G06F19/20 ,  G06F19/24 ,  G16H50/30 ,  Y02A90/26

摘要： In one aspect the invention is a method of testing for one or more colorectal pathologies or one or more subtypes of colorectal pathology (in one embodiment colorectal cancer) in a test individual by providing data corresponding to a level of products of selected biomarkers and applying the data to a formula to provide an indication of whether the test individual has one or more colorectal pathologies or one or more subtypes of colorectal pathology. In some aspects the method is computer based and a computer applies the data to the formula. In other aspects a computer system is configured with instructions that cause the processor to provide a user with the indication of whether the test individual has colorectal pathology. Also encompassed are kits for measuring data corresponding to the products of selected biomarkers which in some embodiments include a computer readable medium. Also encompassed are kits and methods of monitoring therapeutic efficacy of treatments for one or more colorectal pathologies.

摘要翻译： 在一个方面，本发明是通过提供对应于所选生物标志物的产物水平的数据并应用所述生物标记物的一个或多个结直肠病理学或一种或多种结直肠病理学（在一个实施方案中为结肠直肠癌）亚型的方法， 数据提供给公式，以提供测试个体是否具有一种或多种结肠直肠病变或一种或多种结直肠病理学亚型的指示。 在某些方面，该方法是基于计算机的，并且计算机将数据应用于公式。 在其他方面，计算机系统配置有指令，其使得处理器向用户提供测试个体是否具有结肠直肠病理学的指示。 还包括用于测量与所选生物标志物的产物相对应的数据的试剂盒，其在一些实施方案中包括计算机可读介质。 还包括监测一种或多种结肠直肠病变治疗效果的试剂盒和方法。

公开(公告)号：US08142998B2

公开(公告)日：2012-03-27

申请号：US12554141

申请日：2009-09-04

申请人： Choong-Chin Liew ,  Thomas Yager ,  Adam Dempsey ,  Samuel Chao ,  Hongwei Zhang ,  Wayne Marshall

发明人： Choong-Chin Liew ,  Thomas Yager ,  Adam Dempsey ,  Samuel Chao ,  Hongwei Zhang ,  Wayne Marshall

IPC分类号： C12Q1/68 ,  C12P19/34 ,  C12M1/36

CPC分类号： G01N33/564 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14 ,  C12N2310/15 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N2800/105 ,  G01N2800/52

摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The measurement of expression of the products of the biomarkers and combinations of biomarkers demonstrates particular advantage in one or more of the following: (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of OA. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers are within the scope of the invention as are kits containing the polynucleotides and proteins and the use of the polynucleotides and proteins. The biomarker products can be used to identify therapeutic targets for osteoarthritis, and compounds that bind and/or modulate gene activity.

摘要翻译： 本发明涉及新型生物标志物的鉴定和选择以及在骨关节炎和/或在骨关节炎的特定阶段中差异表达的新型生物标志物组合的鉴定和选择，以及选择新型生物标志物组合的方法。 测量生物标志物的产物和生物标志物的组合在以下一个或多个中表现出特别的优点：（a）诊断个体具有关节炎，（b）区分两个阶段的骨关节炎（OA）和（c） 诊断个人具有特定的OA阶段。 与生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质在本发明的范围内，以及含有多核苷酸和蛋白质的试剂盒以及多核苷酸和蛋白质的用途。 生物标记产物可用于鉴定骨关节炎的治疗靶点，以及结合和/或调节基因活性的化合物。

公开(公告)号：US08110358B2

公开(公告)日：2012-02-07

申请号：US12757931

申请日：2010-04-09

申请人： Choong-Chin Liew

发明人： Choong-Chin Liew

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q1/6809 ,  C12Q1/6883 ,  C12Q2600/158 ,  Y10T436/143333

摘要： The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

摘要翻译： 本发明涉及血液中基因转录物的检测和测量。 具体提供的是使用组织特异性引物检测，诊断和监测疾病的一滴血液进行的RT-PCR分析。 本发明还描述了通过其描绘序列和/或定量疾病相关基因的表达水平可以立即进行疾病诊断/预后测试或评估特定治疗方案的效果的方法。

公开(公告)号：US20110223594A1

公开(公告)日：2011-09-15

申请号：US13002007

申请日：2009-06-29

申请人： Peter Vanburen ,  Jun Ma ,  Choong-Chin Liew

发明人： Peter Vanburen ,  Jun Ma ,  Choong-Chin Liew

IPC分类号： C12Q1/68 ,  C07H21/00 ,  G06F19/00

CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16

摘要： The application provides a method of determining a severity of heart failure in a human test subject, by determining a level of RNA encoded by one or more heart failure marker genes in blood of the test subject compared to controls. The application also provides a method of determining survival outcome and allows the ranking of test subjects based on the level of RNA encoded by one or more survival associated genes.

摘要翻译： 该应用提供了通过测定与对照相比测试受试者的血液中的一种或多种心力衰竭标记基因编码的RNA水平来确定人类测试受试者的心力衰竭严重程度的方法。 该应用还提供了一种确定存活结果的方法，并且允许基于由一个或多个存活相关基因编码的RNA的水平来测试受试者的排名。

公开(公告)号：US20110003298A1

公开(公告)日：2011-01-06

申请号：US12757931

申请日：2010-04-09

申请人： Choong-Chin Liew

发明人： Choong-Chin Liew

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： C12Q1/6886 ,  C12Q1/6809 ,  C12Q1/6883 ,  C12Q2600/158 ,  Y10T436/143333

摘要： The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

公开(公告)号：US20110003294A1

公开(公告)日：2011-01-06

申请号：US12757918

申请日：2010-04-09

申请人： Choong-Chin Liew

发明人： Choong-Chin Liew

IPC分类号： C12Q1/68 ,  G01N33/50

CPC分类号： C12Q1/6886 ,  C12Q1/6809 ,  C12Q1/6883 ,  C12Q2600/158 ,  Y10T436/143333

摘要： The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

公开(公告)号：US20100203520A1

公开(公告)日：2010-08-12

申请号：US12587385

申请日：2009-10-05

申请人： Choong-Chin Liew

发明人： Choong-Chin Liew

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q1/6809 ,  C12Q1/6883 ,  C12Q2600/158 ,  Y10T436/143333

摘要： The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.